再生医学市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按治疗、材料、按应用、最终用户、地区和竞争细分

2022 年全球再生医学市场价值为 146.7 亿美元，预计在整个预测期内将实现强劲增长，复合年增长率 (CAGR) 为 9.45%，预计到 2028 年将达到 251.1 亿美元。再生医学、一个新兴领域，专注于替换或修復受损的人体器官或组织。这种治疗方法采用干细胞来恢復缺乏自癒能力的器官和组织的功能。科学家预见在实验室中培育器官和组织的潜力，然后可以安全地移植到人体中。对再生医学的需求不断增长是由于其个人化治疗方法，与传统方法相比，它可以提供更有效的疾病管理。这涵盖了多种医疗技术，包括人造器官、细胞疗法和组织工程。组织工程和生物材料使用植入支架来促进新组织的形成，吸引干细胞以促进具有所需特性的组织发育。细胞疗法利用各种来源的干细胞来修復受损的组织。此外，医疗设备和人造器官为患病器官提供支援。

主要市场驱动因素

增加对研发 (R&D) 活动的投资

市场概况
预测期	2024-2028
2022 年市场规模	146.7亿美元
2028 年市场规模	251.1亿美元
2023-2028 年复合年增长率	9.45%
成长最快的细分市场	组织工程
最大的市场	北美洲

不断增长的研发投资透过促进创新产品的推出推动了市场扩张。投资的增加催生了全面的研发计划，许多新创公司为新疗法和产品获得了资金。这促进了旨在优化研发活动效益的实质合作、合併和伙伴关係。 2022年6月，比利时生物技术公司Galapagos收购了Cell Point和Abound Bib，这是一项旨在加速先进细胞疗法的开发和商业化的策略性倡议。透过整合 Cell Point 和 Abound Bio，Galapagos 获得了创新、可扩展、分散和自动化的护理点细胞治疗供应模式，以及尖端的全人类抗体治疗平台。这些进步使 Galapagos 成为一家综合生物製药公司，有可能颠覆 CAR-T 治疗模式。除了私人实体之外，各国政府和政府资助的研究机构也积极投资该产业，为癌症、帕金森氏症、糖尿病、肾臟疾病、心血管疾病等慢性疾病引入有效的治疗方案。 2022 年 1 月，爱尔兰皇家外科学院从欧盟委员会获得了 226,000 美元的资金，用于开髮用于骨质疏鬆症骨治疗的抗氧化剂离子替代奈米颗粒。

慢性病盛行率增加

心臟病、糖尿病和癌症等慢性疾病的发生率上升预计将推动市场成长。例如，美国疾病管制与预防中心的资料显示，美国有 3,730 万人患有糖尿病。导致糖尿病激增的因素包括生活方式的改变、人口老化和体力活动不足。干细胞生物学利用各种干细胞类型（包括胚胎细胞、种系细胞、间质细胞和诱导多能细胞）为糖尿病治疗提供了一个有前景的途径。

遗传性疾病和创伤紧急情况的发生率不断上升

充血性心臟衰竭、心肌梗塞、帕金森氏症、各种形式的骨质流失和杜氏肌肉营养不良症（DMD）等疾病的日益流行正在推动再生医学市场对细胞疗法的需求。此外，对膀胱、输尿管和尿道重建的自体移植物的依赖也推动了市场的成长。许多公司正在透过合作推进细胞疗法。例如，礼来公司于 2018 年 4 月与 Sigilon Therapeutics 合作开发用于治疗 I 型糖尿病的封装细胞疗法。此类尖端产品的推出将推动细胞疗法的需求并促进再生医学市场的发展。虽然自体、同种异体和异种细胞疗法广泛应用于再生医学市场，但只有有限数量的产品获得 FDA 商业化批准。例如，Fibrocell Science, Inc.的Laviv被批准用于治疗成人中度至重度鼻唇沟皱纹，而Genzyme Corporation的Carticel则用于修復膝盖的症状性软骨缺损。创伤的普遍存在促进了再生医学和器官移植的采用。事故、烧伤和其他创伤病例的增加极大地提振了再生医学市场。根据疾病管制与预防中心的数据，2019 年，与创伤性脑损伤(TBI) 相关的住院人数约为223,135 人，2021 年，有69,473 人因TBI 相关死亡。这些数字相当于超过611 人因TBI 相关住院，176 人因TBI 死亡在美国每天。事故创伤病例的激增推动了全球对再生药物的需求。儘管许多公司已扩展到创伤损伤的再生医学市场，但该领域仍主要用于器官移植。然而，事故护理技术的进步预计将导致预测期内再生医学市场的快速成长。

新技术的出现

3D 列印等新技术的出现预计将推动自体细胞疗法在危及生命的情况下的采用。 Organogenesis, Inc. 开发的 Apligraf 等着名产品利用同种异体细胞治疗溃疡。再生技术的进步推动了干细胞在市场上的应用。心臟动脉、工程膀胱和其他内部结构等器官的创新有助于这项进步。目前许多基于干细胞的疗法正在进行临床试验，显示出组织再生的巨大潜力。市场参与者推出了多项技术来提高干细胞研究效率和商业应用，从而刺激再生医学市场的成长。政府和私人机构的研发计划和投资预计将在预测期内支持市场成长。然而，与再生医学治疗相关的高成本可能会对市场扩张构成障碍。葛兰素史克的腺苷脱氨酶产品会导致严重联合免疫缺陷(ADA-SCID)，而其他公司的基因附加疗法研究，包括GE Healthcare 和Mayo Clinic，则采用锌指核酸酶(ZFN)、CRISPR /Cas9 和mega 核酸酶等核酸酶（MN）修改人类基因组。然而，基因校正可能会对细胞发育和增殖产生意想不到的影响。此外，基因校正治疗的效率会根据目标细胞的基因组而变化，限制了其应用。

主要市场挑战

用于细胞和基因治疗的载体生产不足

目前的向量生成方法通常缺乏可扩展性。满足临床试验和商业化需求可能具有挑战性，特别是针对大量患者群体的治疗。随着再生医学的进步，治疗方法多样化，需要可靠的载体生产方法来生产各种载体，包括腺相关病毒 (AAV) 和慢病毒。

治疗费用高

使用这些产品的治疗成本高昂，加上缺乏报销政策，阻碍了市场的成长。大多数干细胞疗法被归类为实验性或研究性治疗，导致医疗保险覆盖范围有限，并需要大量自付费用。医疗保险专门承保 FDA 批准的疗法（例如同种异体移植）的费用。干细胞治疗的费用差异很大，从 5,000 美元到 50,000 美元不等，受细胞类型、数量、品质和来源等因素的影响。例如，诺华公司的Zolgensma，一种治疗脊髓性肌肉萎缩症的一次性基因疗法，售价为212万美元。由于缺乏保险覆盖，患者必须自掏腰包支付治疗费用或诉诸众筹，从而延误治疗并阻碍市场成长。此外，针对各种遗传性疾病的核准疗法的可用性有限，通常伴随着高昂的费用和潜在的副作用，进一步限制了它们的采用和市场成长。

主要市场趋势

新兴经济体的潜力不断成长

在全球创伤性损伤和器官移植发生率不断上升的推动下，发展中经济体在再生医学市场上呈现巨大的潜力。主要产业参与者策略性地认识到这些经济体中组织工程和再生医学的机会，利用产品发布、批准、协议、合作伙伴关係和合併等策略。儘管由于不利的规范而面临伦理挑战，但发展中经济体预计将采用组织工程和再生技术。

器官移植领域对再生医学的需求不断增长

肾臟移植需求量大，等待名单中 80% 是肾臟病患者。儘管政府努力增加捐赠者数量，但对器官移植的需求仍在持续增加。组织工程和再生医学在满足全球移植需求方面具有巨大潜力。必须克服血管形成和组织讯号传导等挑战才能成功复製原始器官功能。利用组织工程、再生和生物列印技术开发复杂组织甚至整个器官方面取得了明显的进展。鑑于处于不同临床试验阶段的众多产品为未来的商业可用性做好了准备，再生医学产品的商业化前景广阔。

细分市场洞察

治疗趋势

2022年，组织工程将主导全球再生医学市场，占据最大的市场份额。诸如用功能性生活结构取代有缺陷的结构的能力以及治疗以前无法治疗的病症的潜力等优势促成了这种优势。大量的研发投资和持续的创新产品推出预计将推动组织工程领域的需求。

应用洞察

由于全球癌症负担不断增加，肿瘤学将在 2022 年引领再生医学市场。政府和私营部门对癌症研究和先进细胞疗法开发的投资发挥了关键作用。 2023 年 1 月，Calidi Biotherapeutics (CBT) 和 First Light Acquisition Group (FLAG) 联手使用基于干细胞的平台彻底改变溶瘤病毒疗法。在细胞疗法和再生医学进步的推动下，心血管领域预计将显着成长。主要参与者积极开发用于修復、恢復和重建受损心臟组织的再生疗法。采用自体和异体单细胞和混合细胞来研究其对心血管疾病的影响的情况正在增加。此外，还研究了生物製剂、小分子和基因疗法用于再生心臟细胞，进一步推动市场成长。

区域洞察

从地理上看，由于慢性病的高盛行率和先进的医疗基础设施，北美在再生医学市场占据主导地位。相较之下，在医疗保健支出增加以及主要製造商在推出新产品方面进行大量投资的推动下，亚太地区有望快速成长。随着疗法进入临床试验第三阶段，北美再生医学市场正处于成长阶段，未来潜力巨大。这显示出积极的商业化努力。组织工程的有利监管和报销政策表明政府有兴趣支持再生产品的成长。然而，主要出于伦理考虑，与干细胞技术相关的严格监管政策阻碍了胚胎干细胞的采用，为市场成长带来了挑战。

目录

第 1 章：治疗概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球再生医学市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按治疗（干细胞治疗、基因治疗、组织工程以及小分子和生物疗法）
  • 依材料（合成材料、生物衍生材料、基因工程材料及药品）
  • 按应用（心血管、肿瘤、肌肉骨骼、伤口癒合、眼科等）
  • 按最终用户（医院、专科中心、学术和研究机构）
  • 按地区
  • 按公司划分 (2022)
• 市场地图

第 6 章：北美再生医学市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 透过治疗
  • 按材质
  • 按应用
  • 按最终用户
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲再生医学市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 透过治疗
  • 按材质
  • 按应用
  • 按最终用户
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区再生医学市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 透过治疗
  • 按材质
  • 按应用
  • 按最终用户
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲再生医学市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 透过治疗
  • 按材质
  • 按应用
  • 按最终用户
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲再生医学市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 透过治疗
  • 按材质
  • 按应用
  • 按最终用户
• MEA：国家分析
  • 南非再生医学
  • 沙乌地阿拉伯再生医学
  • 阿联酋再生医学

第 11 章：市场动态

第 12 章：市场趋势与发展

第 13 章：全球再生医学市场：SWOT 分析

第14章：竞争格局

• 商业概览
• 服务产品
• 最近的发展
• 主要人员
• SWOT分析
  • Stryker Corporation
  • Athersys, Inc.
  • Integra Lifesciences Corporation
  • Isto Biologics (Isto Biologics Medical Systems, Inc.)
  • Organogenesis Inc.
  • CryoLife, Inc.
  • Medtronic plc
  • US Stem Cell, Inc.
  • Zimmer Biomet Holdings, Inc.
  • 3M Company

第 15 章：策略建议

第 16 章：关于我们与免责声明

The Global Regenerative Medicine Market was valued at USD 14.67 Billion in 2022 and is projected to experience robust growth throughout the forecast period, with a Compound Annual Growth Rate (CAGR) of 9.45% and expected to reach USD 25.11 Billion through 2028. Regenerative medicine, an emerging field, concentrates on the replacement or repair of damaged human organs or tissues. Stem cells are employed in this therapeutic approach to restore function to organs and tissues that lack the ability to self-heal. Scientists foresee the potential for growing organs and tissues in laboratories, which can then be safely transplanted into the human body. The escalating demand for regenerative medicine is due to its personalized treatment approach, offering more effective disease management compared to conventional methods. This encompasses a variety of medical techniques including artificial organs, cellular therapies, and tissue engineering. Tissue engineering and biomaterials use implanted scaffolds to facilitate the creation of new tissue, attracting stem cells to foster tissue development with desired characteristics. Cellular therapies employ stem cells from various sources to repair damaged tissues. Moreover, medical devices and artificial organs provide support to ailing organs.

Key Market Drivers

Increasing Investments in Research and Development (R&D) Activities

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 14.67 Billion
Market Size 2028	USD 25.11 Billion
CAGR 2023-2028	9.45%
Fastest Growing Segment	Tissue Engineering
Largest Market	North America

Growing investments in R&D have driven market expansion by fostering innovative product launches. This uptick in investment has led to comprehensive R&D initiatives, with numerous start-up companies securing funding for novel therapies and products. This has facilitated substantial collaborations, mergers, and partnerships geared towards optimizing the benefits of R&D activities. In June 2022, Belgian biotech company Galapagos acquired Cell Point and Abound Bib, a strategic move aimed at accelerating the development and commercialization of advanced cell therapies. By integrating Cell Point and Abound Bio, Galapagos gains access to innovative, scalable, decentralized, and automated point-of-care cell therapy supply models, along with a cutting-edge fully human antibody-based therapeutics platform. These advancements position Galapagos as an integrated biopharmaceutical firm with the potential to disrupt the CAR-T treatment paradigm. Beyond private entities, various governments and government-funded research institutions are actively investing in this industry to introduce effective treatment options for chronic diseases like cancer, Parkinson's disease, diabetes, renal diseases, cardiovascular diseases, and others. In January 2022, the Royal College of Surgeons in Ireland secured USD 226,000 in funding from the European Commission for the development of antioxidant-ion substituted nanoparticles for osteoporotic bone treatment.

Increasing Prevalence of Chronic Conditions

The rising occurrence of chronic conditions like heart disease, diabetes, and cancer is expected to propel market growth. For example, data from the Centers for Disease Control and Prevention reveals that 37.3 million individuals in the United States are living with diabetes. Contributing factors to the diabetes surge include changing lifestyles, an aging population, and insufficient physical activity. Stem cell biology offers promising avenues for diabetes treatment, employing various stem cell types including embryonic, germline, mesenchymal, and induced pluripotent cells.

Growing Incidence of Genetic Disorders and Trauma Emergencies

The increasing prevalence of diseases such as congestive heart failure, myocardial infarction, Parkinson's disease, various forms of bone loss, and Duchenne muscular dystrophy (DMD) is driving the demand for cell therapy in the regenerative medicine market. Additionally, reliance on autologous grafts for bladder, ureter, and urethra reconstruction fuels market growth. Numerous companies are pushing forward with cell therapy through collaborations. For instance, Eli Lilly partnered with Sigilon Therapeutics in April 2018 to develop encapsulated cell therapies for type I diabetes treatment. The introduction of such cutting-edge products is poised to drive demand for cell therapies and boost the regenerative medicine market. While autologous, allogenic, and xenogenic cell therapies are widely used in the regenerative medicine market, only a limited number of products have received FDA approval for commercialization. For instance, Laviv from Fibrocell Science, Inc. is approved for treating moderate-to-severe nasolabial fold wrinkles in adults, while Carticel from Genzyme Corporation is used for symptomatic cartilage defect repair in the knees. The prevalence of trauma injuries has contributed to increased adoption of regenerative medicine and organ transplantation. The rise in accidents, burn injuries, and other trauma cases has significantly bolstered the regenerative medicine market. According to the Center for Disease Control and Prevention, Traumatic Brain Injury (TBI)-related hospitalizations reached approximately 223,135 in 2019, with 69,473 TBI-related deaths in 2021. These figures equate to over 611 TBI-related hospitalizations and 176 TBI-related deaths per day in the United States. This surge in accident trauma cases has driven global demand for regenerative medicines. While many companies have expanded into the regenerative medicine market for trauma injuries, this segment is still primarily used in organ transplantation. However, advancements in accident care technologies are expected to lead to rapid growth in the regenerative medicine market during the forecast period.

Emergence of New Technologies

The emergence of novel technologies such as 3D printing is expected to drive the adoption of autologous cell therapies for life-threatening conditions. Notable products like Apligraf, developed by Organogenesis, Inc., utilize allogenic cells for treating ulcers. Regenerative technologies' progress fuels stem cell applications in the market. Innovations in organs like heart arteries, engineered bladders, and other internal structures contribute to this advancement. Numerous stem cell-based therapies are currently undergoing clinical trials, demonstrating substantial potential for tissue regeneration. Market players have introduced several technologies to enhance stem cell research efficiency and commercial applications, thereby stimulating the growth of the regenerative medicine market. Government and private agency R&D programs and investments are expected to support market growth in the forecast period. However, the high costs associated with regenerative medicine treatments could pose a barrier to market expansion. GlaxoSmithKline's product for adenosine deaminase, which causes severe combined immunodeficiency (ADA-SCID), and other companies' gene additive therapies research, including GE Healthcare and Mayo Clinic, employ nucleases like zinc finger nucleases (ZFNs), CRISPR/Cas9, and mega nucleases (MNs) to modify the human genome. However, gene correction can have unintended effects on cell development and proliferation. Additionally, the efficiency of gene correction treatment varies depending on the targeted cells' genome, limiting its application.

Key Market Challenges

Insufficient Vector Production for Cell and Gene Therapy

Current vector production methods often lack scalability. Meeting clinical trial and commercialization demands can be challenging, particularly for therapies targeting large patient populations. As regenerative medicine advances, therapeutic approaches diversify, necessitating reliable vector production methods for various vectors, including adeno-associated viruses (AAVs) and lentiviruses.

High Treatment Costs

The high costs associated with treatments employing these products, coupled with the absence of reimbursement policies, hinder market growth. Most stem cell therapies are categorized as experimental or investigational treatments, leading to limited Medicare insurance coverage and significant out-of-pocket expenses. Medicare exclusively covers expenses for FDA-approved therapies such as allogeneic transplantation. Stem cell therapy costs vary widely, ranging from USD 5,000 to USD 50,000, influenced by factors such as cell type, quantity, quality, and source. For instance, Novartis' Zolgensma, a one-time gene therapy for spinal muscular atrophy, carries a price tag of USD 2.12 million. The lack of insurance coverage leaves patients to cover treatment costs out-of-pocket or resort to crowdfunding, delaying treatment and impeding market growth. Additionally, the availability of approved therapies for various genetic disorders is limited, often accompanied by significant expenses and potential side effects, further constraining their adoption and market growth.

Key Market Trends

Growing Potential in Emerging Economies

Developing economies present substantial potential in the regenerative medicine market, driven by the increasing incidence of traumatic injuries and organ transplants worldwide. Key industry players strategically recognize opportunities in tissue engineering and regenerative medicine within these economies, leveraging tactics such as product launches, approvals, agreements, partnerships, and mergers. Despite ethical challenges due to unfavorable norms, developing economies are anticipated to embrace tissue engineering and regeneration technology.

Rising Demand for Regenerative Medicine in Organ Transplantation

Kidney transplants are in high demand, with 80% of the waiting list comprising kidney patients. Despite government efforts to increase donor numbers, the demand for organ transplants continues to rise. Tissue engineering and regenerative medicine hold significant potential to address this global demand for transplants. Challenges like vascularization and tissue signaling must be overcome to replicate original organ functions successfully. Progress is evident in the development of complex tissues and even whole organs using tissue engineering, regeneration, and bioprinting technologies. Commercializing regenerative medicine products holds promise, given numerous products in various clinical trial phases, poised for future commercial availability.

Segment Insights

Therapeutic Trends

Tissue engineering dominated the global regenerative medicine market in 2022, claiming the largest market share. Advantages such as the ability to replace faulty structures with functional living counterparts and the potential to treat previously untreatable conditions contribute to this dominance. Significant R&D investments and ongoing innovative product launches are expected to drive demand in the tissue engineering segment.

Application Insights

Oncology led the regenerative medicine market in 2022 due to the growing global cancer burden. Government and private sector investments in cancer research and advanced cell therapy development played a pivotal role. In January 2023, Calidi Biotherapeutics (CBT) and First Light Acquisition Group (FLAG) joined forces to revolutionize oncolytic virotherapies using stem cell-based platforms. The cardiovascular segment is projected to experience notable growth, fueled by advancements in cell-based therapies and regenerative medicine. Key players actively develop regenerative therapies for repairing, restoring, and revascularizing damaged heart tissues. The adoption of autologous and allogeneic single and mixed cells for studying their effects on cardiovascular diseases is on the rise. Additionally, biologics, small molecules, and gene therapy are investigated for regenerating heart cells, further driving market growth.

Regional Insights

Geographically, North America dominates the regenerative medicine market due to the high prevalence of chronic diseases and advanced healthcare infrastructure. In contrast, the Asia-Pacific region is poised for rapid growth, driven by increased healthcare spending and significant investments by major manufacturers in introducing new products. North America's regenerative medicine market is in a growth phase with potential for the future, as therapies advance to the third phase of clinical trials. This indicates active commercialization efforts. Favorable regulatory and reimbursement policies for tissue engineering demonstrate government interest in supporting regenerative product growth. However, strict regulatory policies related to stem cell technologies, primarily due to ethical concerns, hamper the adoption of embryonic stem cells, posing challenges to market growth.

Key Market Players

• Stryker Corporation
• Athersys, Inc.
• Integra Lifesciences Corporation
• Isto Biologics (Isto Biologics Medical Systems, Inc.)
• Organogenesis Inc.
• CryoLife, Inc.
• Medtronic plc
• U.S. Stem Cell, Inc.
• Zimmer Biomet Holdings, Inc.
• 3M Company

Report Scope:

In this report, the Global Regenerative Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Regenerative Medicine Market, By Therapy:

• Stem Cell Therapy
• Gene Therapy
• Tissue Engineering
• Small Molecule & Biologic

Regenerative Medicine Market, By Material:

• Synthetic Material
• Biologically Derived Material
• Genetically Engineered Material
• Pharmaceuticals

Regenerative Medicine Market, By Application:

• Cardiovascular
• Oncology
• Musculoskeletal
• Wound Healing
• Ophthalmology
• Others

Regenerative Medicine Market, By End User:

• Hospitals
• Specialty Centres
• Academic & Research Institutes

Regenerative Medicine Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Regenerative Medicine Market.

Available Customizations:

• Global Regenerative Medicine market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Therapy Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Regenerative Medicine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (Stem Cell Therapy, Gene Therapy, Tissue Engineering, And Small Molecule & Biologic)
  • 5.2.2. By Material (Synthetic Material, Biologically Derived Material, Genetically Engineered Material, And Pharmaceuticals)
  • 5.2.3. By Application (Cardiovascular, Oncology, Musculoskeletal, Wound Healing, Ophthalmology, And Others)
  • 5.2.4. By End User (Hospitals, Specialty Centres, Academic & Research Institutes)
  • 5.2.5. By Region
  • 5.2.6. By Company (2022)
• 5.3. Market Map

6. North America Regenerative Medicine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Material
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Regenerative Medicine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Material
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Regenerative Medicine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Material
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Regenerative Medicine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Material
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Regenerative Medicine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Material
  • 7.2.3. By Application
  • 7.2.4. By End User
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Regenerative Medicine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Material
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Regenerative Medicine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Material
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Regenerative Medicine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Material
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. France Regenerative Medicine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Material
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Regenerative Medicine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Material
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Regenerative Medicine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Material
  • 8.2.3. By Application
  • 8.2.4. By End User
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Regenerative Medicine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Material
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Regenerative Medicine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Material
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Regenerative Medicine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Material
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Regenerative Medicine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Material
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Regenerative Medicine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Material
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Regenerative Medicine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Material
  • 9.2.3. By Application
  • 9.2.4. By End User
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Regenerative Medicine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Material
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Regenerative Medicine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Material
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Regenerative Medicine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Material
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Regenerative Medicine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Material
  • 10.2.3. By Application
  • 10.2.4. By End User
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Regenerative Medicine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Material
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Regenerative Medicine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Material
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Regenerative Medicine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Material
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

12. Market Trends & Developments

13. Global Regenerative Medicine Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Services Offerings
• 14.3. Recent Developments
• 14.4. Key Personnel
• 14.5. SWOT Analysis
  • 14.5.1. Stryker Corporation
  • 14.5.2. Athersys, Inc.
  • 14.5.3. Integra Lifesciences Corporation
  • 14.5.4. Isto Biologics (Isto Biologics Medical Systems, Inc.)
  • 14.5.5. Organogenesis Inc.
  • 14.5.6. CryoLife, Inc.
  • 14.5.7. Medtronic plc
  • 14.5.8. U.S. Stem Cell, Inc.
  • 14.5.9. Zimmer Biomet Holdings, Inc.
  • 14.5.10. 3M Company

15. Strategic Recommendations

16. About Us & Disclaimer